Kinsey Pharmaceuticals is the China Genetic Engineering Drug Quality Management Demonstration Center, the National Genetic Engineering New Drug Incubation Base, the second-class winner of the National Science and Technology Progress Award, and has the Asian recombinant human growth hormone production base.
Jinsai Pharmaceutical is a holding subsidiary of Changchun High-tech (stock code 000661), with its administrative headquarters and production headquarters located in Changchun.
Introduction to Kinsey
The journey of Kinsey people begins with a brave beginning. Focus and excellence run through Jinsai Pharmaceutical's 20-year development history. There are 7 million short children across the country who dream of growing taller, and 43 million families face infertility problems. They missed their dreams, and their lives should have no regrets.
Growth hormone is the core protein that controls human growth. We explore growth potential and make dreams no longer out of reach. Domestic growth hormone powder was launched in 1998, growth hormone liquid was launched in 2005, polyethylene glycol long-acting growth hormone was launched in 2014, domestic recombinant human follicle-stimulating hormone was launched in 2015, and growth hormone invisible needle electronic injection pen was launched in 2016. Today, Kinsey owns Asia's recombinant human growth hormone production line and is the production base for three series of recombinant human growth hormone: long-acting, liquid, and powder. We have helped 200,000 short children around the world realize their dream of growing taller.
The craftsmanship spirit of focusing on excellence and pursuing ideals has been the driving force and soul of our continuous progress over the past 20 years. Jinsai Pharmaceutical's product quality internal control standards are comprehensively superior to national standards, and many products have been selected by the Central Inspection and Quarantine Bureau as providers of national standard products. Jinsai Pharmaceutical is a national genetic engineering drug quality management demonstration center and a national genetic engineering new drug incubation base. In 2015, Jinsai Pharmaceutical won the second prize of the National Science and Technology Progress Award.
We continue to pay attention to the development of academic disciplines in the field and provide academic and educational support for young and middle-aged pediatric doctors. We also shoulder the social responsibility of improving the height and physical fitness of the people and continue to contribute warmth.
We invest huge amounts of money every year in the research and development and construction of future product lines. Currently, our products under development cover the fields of reproduction, oncology, autoimmunity, ophthalmology, nervous system and metabolic diseases. In order to improve human health and quality of life, we forge ahead without hesitation.
In the future, we will continue to pay attention to the field of children's height growth, so that Chinese people can grow 5 centimeters taller. We will also be committed to the research and development of product lines in the field of infertility, becoming a leading brand in this field in the next five years, and solving the infertility problem of older women. We will also focus on the field of anti-aging to make the Chinese elderly who are about to enter an aging society healthy and happy. This is our great dream. We will use focus and wisdom to show the world our shocking national power.
Main products
Jinsai Pharmaceutical is a typical enterprise that emerged from my country's innovation-driven development strategy during the "Twelfth Five-Year Plan" period. In 1998, Kinsey Pharmaceuticals invented gene recombinant secretory expression technology and launched domestic recombinant human growth hormone powder injection, successfully filling the domestic gap. In 2005, Kinsey Pharmaceuticals developed recombinant human growth hormone amorphous protein stabilization technology, which solved the problem of growth hormone being unstable in aqueous solution, and launched Asian recombinant human growth hormone water injection, which not only has a high-quality natural structure, but also induces antibodies. The detection rate is zero. In 2008, the company launched a new drug with a national invention patent, the world's only rhGM-CSF gel. In 2014, Kinsey Pharmaceuticals created the polyethylene glycol growth hormone conjugation technology, took the lead in launching the world's long-acting recombinant human growth hormone, and obtained three national invention patents, ending the need for daily injections for short children to grow taller in the past 60 years. The history of growth hormone treatment is of epoch-making significance. In 2015, Jinsaiheng, the ovulation-stimulating recombinant human follicle-stimulating hormone, was launched in China, solving the long-term dependence on imported follicle-stimulating hormone. In 2016, Kinsey Pharmaceutical launched a growth hormone invisible needle electronic injection pen to eliminate children's fear of injections, improve children's compliance, and ensure better treatment effects. From "national" to "Asia" to "global", Jinsai people have achieved it step by step by adhering to the spirit of innovation and breakthrough.